![]() |
市场调查报告书
商品编码
1519456
2024-2032年按药物类别、适应症(胃食道逆流或胃灼热、便秘、腹泻、晕动病等)、最终使用者和地区分類的胃肠道非处方药市场Gastrointestinal OTC Drugs Market by Drug Class, Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, and Others), End User, and Region 2024-2032 |
IMARC Group年全球胃肠道非处方药市场规模达420亿美元。胃肠道疾病盛行率的上升、大众对消化健康的认识不断提高以及先进配方的最新开发是推动市场的一些关键因素。
胃肠道非处方药 (OTC) 是指缓解胃肠道症状并促进整体消化健康的非处方药。它包括泻药、抗酸剂、H2 阻断剂、质子帮浦抑制剂 (PPI)、止吐药、肠道抗发炎药和止泻药。胃肠道非处方药广泛用于治疗消化不良、便秘、胃灼热、腹泻、晕动病、胃酸逆流、噁心、肠躁症(IBS)和腹痛。它是一种经济高效、方便且易于使用的产品,可立即缓解症状、提高患者舒适度并允许自我管理。胃肠道非处方药也有助于改善肠道健康,恢復有益细菌,预防未来的併发症,并最大限度地减轻各种症状的严重程度,例如疼痛、腹胀、腹部不适和呕吐。
由于久坐的生活方式和不健康的饮食习惯导致胃肠道疾病的盛行率不断上升,这是推动市场成长的关键因素之一。胃肠道非处方药广泛用于治疗感染、消化不良、急性腹泻、胃灼热、胃食道逆流(GERD)、便秘、腹胀和孕吐。此外,由于大众对消化健康的认识不断增强,用于改善消化、促进肠道健康、确保营养物质适当分解和吸收的产品应用不断增加,也为市场成长提供了动力。与此一致的是,自我照护和消费者赋权以管理福祉和预防未来健康併发症的新兴趋势正在成为另一个成长诱导因素。此外,最近开发的先进製剂,如泡腾片、液体、混悬剂、薄膜条和咀嚼产品,增强了药物的有效性,增加了吸收,并减少了给药频率,对市场成长产生了积极影响。除此之外,泡罩包装、可重复密封袋和单剂量包装等方便且适合旅行的包装的引入正在推动市场成长。除此之外,消费者对非侵入性治疗的日益偏好正在促进解决常见消化问题并提供即时缓解的产品需求。此外,一些製造商透过电视广告、社群媒体、有影响力的行销和名人代言积极的促销和品牌活动正在加强市场的成长。其他因素,包括老年人口的增加、消费者支出能力的增强以及电子商务平台上产品的便捷获取,预计将推动市场成长。
The global gastrointestinal OTC drugs market size reached US$ 42.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 60.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4% during 2024-2032. The rising prevalence of gastrointestinal disorders, increasing awareness among the masses regarding digestive health, and the recent development of advanced formulations represent some of the key factors driving the market.
Gastrointestinal over-the-counter (OTC) drugs refer to non-prescription medications that alleviate gastrointestinal symptoms and promote overall digestive wellness. It includes laxatives, antacids, H2 blockers, proton pump inhibitors (PPIs), anti-emetics, bowel anti-inflammatory, and anti-diarrheal medications. Gastrointestinal OTC drugs are widely used to treat indigestion, constipation, heartburn, diarrhea, motion sickness, acid reflux, nausea, irritable bowel syndrome (IBS), and abdominal pain. It is a cost-effective, convenient, and easily accessible product that provides immediate relief, enhances patient comfort, and allows self-management. Gastrointestinal OTC drugs also aid in improving gut health, restoring beneficial bacteria, preventing future complications, and minimizing the severity of various symptoms, such as pain, bloating, abdominal discomfort, and vomiting.
The rising prevalence of gastrointestinal disorders due to sedentary lifestyles and unhealthy eating habits is one of the key factors providing a thrust to the market growth. Gastrointestinal OTC drugs are widely used to treat infections, dyspepsia, acute diarrhea, heartburn, gastroesophageal reflux disease (GERD), constipation, bloating, and morning sickness. Furthermore, the increasing product applications to improve digestion, promote gut health, and ensure proper breakdown and absorption of nutrients, owing to the growing awareness among the masses regarding digestive health, is providing an impetus to the market growth. In line with this, the emerging trends of self-care and consumer empowerment to manage well-being and prevent future health complications are acting as another growth-inducing factor. Additionally, the recent development of advanced formulations, such as effervescent tablets, liquids, suspensions, film strips, and chewable products, which enhances the effectiveness of the drugs, increases absorption, and reduces the frequency of dosing, is positively influencing the market growth. Besides this, the introduction of convenient and travel-friendly packaging, such as blister packs, resealable pouches, and single-dose packets, is propelling the market growth. Apart from this, the rising consumer preference for non-invasive treatments is facilitating product demand to manage common digestive issues and provide immediate relief. Moreover, aggressive promotional and branding campaigns by several manufacturers through television (TV) commercials, social media, influencer marketing, and celebrity endorsement is strengthening the market growth. Other factors, including the rising geriatric populations, increasing expenditure capacities of consumers, and easy availability of products across e-commerce platforms, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global gastrointestinal OTC drugs market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug class, indication, and end user.
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
The report has provided a detailed breakup and analysis of the gastrointestinal OTC drugs market based on the drug class. This includes laxatives, gastrointestinal cancer treatments, gastric acid reducers, anti-diarrheal, proton pump inhibitors, H2 inhibitors, gastric acid neutralizers, bowel anti-inflammatory, and anti-emetics.
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Others
A detailed breakup and analysis of the gastrointestinal OTC drugs market based on the indication has also been provided in the report. This includes gastroesophageal reflux disease (GERD) or heartburn, constipation, diarrhea, motion sickness, and others.
Hospitals
Clinics
Others
A detailed breakup and analysis of the gastrointestinal OTC drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and others.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for gastrointestinal OTC drugs. Some of the factors driving the North America gastrointestinal OTC drugs market included the rising prevalence of gastrointestinal disorders, increasing awareness among the masses, and various product innovations.
The report has also provided a comprehensive analysis of the competitive landscape in the global gastrointestinal OTC drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Boehringer Ingelheim GmbH, Johnson & Johnson, Prestige Consumer Healthcare Inc., Purdue Pharma L.P, Sanofi, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.